Regeneron Pharmaceuticals Inc's stock saw a significant jump after receiving positive analyst ratings and promising results from clinical trials.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up today, gaining 3.63% and closing at CA$806.63. This increase follows a new 'Buy' rating from UBS, which pointed out the company's undervalued potential tied to its blockbuster drug Dupixent.
Investor takeaway: Investors are optimistic about UBS's positive outlook and the chance for Regeneron to benefit from future advancements in its drug pipeline, especially with the next-generation candidates for Dupixent.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$77.54B
P/E
18.6x
Div. yield
0.48%
Div. / share
$3.64
52W high
$859.34
52W low
$563.22
1W change
+4.88%
Beta
0.15
Analyst Price Targets
Based on 27 analysts covering REGN · as of Oct 14, 2026
Wall Street analysts forecast REGN stock price to rise 10.4% over the next 12 months.
Consensus
Buy4.15 / 5.00
Avg. Target
C$859.69
+10.4% Upside
Previously C$859.04 on Oct 12, 2026
Current Price
C$778.36
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
29.1%
Annualized
90-Day Vol
29.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$930.54
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$826.10 | C$747.09 – C$913.46 |
| 60 trading days | C$876.76 | C$760.57 – C$1010.71 |
| 90 trading days | C$930.54 | C$781.83 – C$1107.53 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
3.63% Increase in Regeneron Stock
The stock's rise reflects positive sentiment from analysts and market optimism regarding Regeneron's future drug pipeline.
Bull case
The new Buy rating from UBS indicates significant upside potential for Regeneron, with a price target of $978. Analysts believe that the ongoing development of follow-on Dupixent treatments could fill potential revenue gaps and extend exclusivity beyond 2031.
Bear case
While the outlook is positive, investors should stay cautious about the competitive landscape and the risks involved in drug development, which could affect future earnings and stock performance.
Advertisement
UBS Initiates Coverage with a Buy Rating
UBS has resumed coverage of Regeneron Pharmaceuticals with a Buy rating, stating that the market undervalues the potential of Dupixent's future developments. Analyst Joon Lee noted that the company’s next-generation Dupixent candidates could greatly boost its revenue streams and extend exclusivity, which is vital for maintaining a competitive edge.
Positive Clinical Trial Results Boost Confidence
Recent positive results from clinical trials of Pasatru, a treatment for fibrodysplasia ossificans progressiva (FOP), have also strengthened investor confidence. The long-term efficacy and safety data presented at a recent conference highlight Regeneron's commitment to innovation and its ability to tackle rare diseases, further solidifying its market position.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
